- Home
- CNTX vs ELUT Comparison
CNTX vs ELUT Comparison
Compare CNTX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | ELUT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 15 | 26 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 41.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNTX | ELUT |
|---|---|---|
| Price | $0.59 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $6.60 | $6.00 |
| AVG Volume (30 Days) | ★ 2.7M | 92.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.39 | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.50 |
| 52 Week High | $3.62 | $2.60 |
Technical Indicators
Market Signals| Indicator | CNTX | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 20.39 | 45.11 |
| Support Level | N/A | $0.86 |
| Resistance Level | $1.30 | $0.99 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 3.80 | 24.24 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.